Objectives: Heritability in the risk for developing posttraumatic stress disorder (PTSD) has been established, but most genome-wide association studies (GWASs) of PTSD involve relatively small sample sizes and limited identification of associated genetic loci. This report describes the methodology of a Veterans Affairs (VA) Cooperative Studies Program GWAS of PTSD among combat-exposed U.S. veterans.
Military combat exposure and sexual trauma are strong risk factors for developing PTSD (Jorge, 2015; Phillips, Leardmann, Gumbs, & Smith, 2010; Zamorski & Boulos, 2014) . Thus, although the prevalence of PTSD in the U.S. civilian population is approximately 6% (Goldstein et al., 2016) , the lifetime prevalence of PTSD in combatexposed U.S. veterans is estimated to be as high as 32% (Wisco et al., 2014) . Vietnam combat veterans reportedly have a lifetime PTSD prevalence of 19-31% (Gates et al., 2012; Murphy, Iversen, & Greenberg, 2008) , with persistent/chronic PTSD estimated at 5-17% (Gates et al., 2012; Marmar et al., 2015; Murphy et al., 2008) .
The PTSD prevalence among combat-exposed veterans deployed to Iraq or Afghanistan varies widely, depending on the military branch and PTSD definition used-a meta-analysis of 33 studies, including nearly 5 million veterans, reported a prevalence of 23% (Fulton et al., 2015) .
PTSD is influenced by genetic factors, as demonstrated by twin
and other genetic epidemiology studies (Pitman et al., 2006; Rodgers & Bale, 2015; Smoller, 2016) . Knowledge of the specifics of these genetic factors would yield a variety of benefits, ranging from improved biological understanding and better ability to differentiate disorders that are genetically related from those that are genetically distinct, to discovering possible pharmacological targets (Stein, 2018; Stein & Smoller, 2018) . The best method for identifying these genetic risk factors is through genome-wide approaches, such as genomewide association studies (GWASs). In a little over a decade, GWASs, when adequately powered, have yielded genetic clues across essentially the entire spectrum of genetically complex traits including mental health disorders (Sullivan et al., 2018) .
Several GWASs of PTSD have been conducted recently (Almli et al., 2015; Ashley-Koch et al., 2015; Daskalakis, Rijal , 2015) . The sample sizes in GWASs to date have varied, with the largest being a meta-analysis of 20,730 persons (Duncan et al., 2018) .
Replication of primary risk loci for PTSD has been a challenge, presumably because of small sizes of discovery and replication samples (Banerjee, Morrison, & Ressler, 2017; Sheerin, Lind, Bountress, Nugent, & Amstadter, 2017) .
The current project investigates the genetics of PTSD using the Veterans Affairs (VA)-based Million Veteran Program (MVP; Gaziano et al., 2016) , designed to enable study of how genes affect health by building a mega-biobank of DNA samples and health information.
The VA also has a long-established history of successfully using electronic health record (EHR) systems in research (Brown, Lincoln, Groen, & Kolodner, 2003) , providing an unparalleled opportunity to link participants' genetic data to clinical outcomes.
The current study, "Genomics of Posttraumatic Stress Disorder in Veterans," supported by the VA Cooperative Studies Program (CSP) as CSP study #575B, is focused on a GWAS of PTSD in a large sample of combat-exposed U.S. veterans. Recognizing considerable uncertainty associated with PTSD diagnosis when determined from EHRs alone (Holowka et al., 2014; Ouyang, Apley, & Mehrotra, 2016) , a probabilistic methodology (Sinnott et al., 2014 ) is used to estimate PTSD caseness and noncaseness (Harrington et al., in press) and to account for phenotypic misclassification in the power and sample size calculations for the GWAS.
| METHODS

| Overview
This study was approved by the Institutional Review Boards at VA Medical Centers in Boston, MA, San Diego, CA, and West Haven, CT. Using a case-control design, genotype is the main explanatory variable, and several phenotype definitions (trait formulations), including lifetime PTSD diagnosis, are the outcome variables. The primary analysis will focus on combat-exposed PTSD cases and combatexposed non-PTSD controls, selected from >353,000 genotyped participants in the MVP. The restriction to combat-exposed cases and combat-exposed controls promotes an unbiased comparison, even if certain participants have noncombat (e.g., early-life and later-in-life) trauma that may have caused or contributed to their PTSD.
| Algorithm for selecting cases and controls
Inclusion criteria for selection were history of military deployment and combat exposure. The only exclusion criterion was evidence of schizophrenia or bipolar disorder. Information was obtained from a combination of self-reports in the MVP Baseline and Lifestyle questionnaires (Gaziano et al., 2016) , together with clinical and administrative data from the VA EHR.
From a pragmatic perspective, given the projected sample size in the tens of thousands, automated PTSD phenotyping by means of an EHR-based algorithm would be more practicable than face-to-face or telephone interviews, which are both resource intensive and timeconsuming. For example, telephone interviews require approximately 1 hr per participant (not including time for preinterview arrangements and postinterview analyses), with the added burden of being potentially a source of psychological discomfort to study participants. Thus, given the size of the MVP participant pool, feasibility and affordability become major, if not prohibitive, concerns. Conversely, EHR-based diagnoses do not involve patient contact, and after algorithms have been properly calibrated and are shown to be sufficiently robust, large populations can be analyzed in little time and at low cost.
Potential cases and controls were therefore identified from the VA EHR using the algorithm summarized below (see Figure 1 ) and described elsewhere (Harrington et al., in press ). To develop and assess its predictive capability, reference data were generated by identifying confirmed PTSD cases and controls from 500 in-depth VA EHR reviews, conducted by five experts in PTSD diagnosis at VA Medical Centers in Boston, MA, San Diego, CA, and West Haven, CT. Evidence of PTSD from the DSM-IV PTSD Checklist (PCL) score (Forbes, Creamer, & Biddle, 2001 ) on the MVP Lifestyle Survey was also used, when available. Veterans who met some PTSD criteria, but could not clearly be classified as cases or controls, were considered "possible" cases. Finally, 125 (25%) of the charts were independently rated by two reviewers to establish interrater reliability.
Based on these chart review results as the reference standard, and using the same three PTSD classes, a probabilistic-based algorithm was constructed for automated selection of PTSD cases and controls from the MVP source population (Harrington et al., in press ).
In particular, symmetric multinomial logistic regression was used, which models a participant's conditional probability π k of "belonging" to class k (=case, control, and possible case) given the predictor x for the participant, that is, Pr(PTSD status = k|x), expressed as (Huttunen, Manninen, Kauppi, & Tohka, 2013) 
where the p-dimensional vector x contains the covariates of interest, K is the number of classes, and β k0 and β k = (β k1 , β k2 , …, β kp ) T are the coefficients of the model for the kth class. The covariates were selected based on their potential association with PTSD. The regression coefficients were estimated using the least absolute shrinkage and selection operator (LASSO) penalized multinomial logistic regression, with 10-fold cross validation. This method simultaneously selects predictors to be retained and estimates the corresponding regression coefficients {β kj } (Wu, Chen, Hastie, Sobel, & Lange, 2009 ).
After the best fit model is derived, Equation (1) gives the participant's estimated probability of belonging to each of the three PTSD classes ( Figure 1 ). Considerable flexibility exists regarding use of these probabilities to assign PTSD status. For example, the predicted class b k could be defined as the maximum of the three probabilities, that is,
The results obtained using this definition are reported in Harrington et al. (in press ).
For application to CSP#575B, a more conservative rule was adopted to minimize false-positive and false-negative designations. Specifically, b k is defined as the class for which the probability is greater than a minimal or threshold value, π min , which necessarily must be ≥0.5 to ensure uniqueness of the prediction. Thus, b k ¼ k such that π k > π min ≥ 0:5; where π min was optimized as discussed below.
| Optimizing π min for case-control GWAS
The optimal threshold probability (π opt ), defined as the π min that maximized the statistical power to detect association between single nucleotide polymorphisms (SNPs) and disease (PTSD), was obtained as follows. For a given π min , the power was computed from the predicted number of PTSD cases and controls obtained with Equation ( 
| Sensitivity analyses
In planned GWAS analyses, although our primary analysis will classify PTSD as a binary yes/no trait, we will also consider PTSD as an ordinal trait, based on the probability of PTSD caseness; this reclassification should improve statistical power. Other analyses will help determine the degree to which comorbidity or sub-components of the PTSD syndrome (e.g., hyperarousal, re-experiencing, sleep disorder, and alcohol use disorder) appears to explain particular genetic findings.
| Telephone interviews (CAPS-5)
To validate and potentially refine the algorithm, clinicians are conducting telephone interviews in a sample of algorithm-predicted probable cases and probable controls, using the DSM-5-compatible 
| Genotyping
Details regarding collection, shipping, and storage of biospecimens, and specifics of the MVP microarray, have been described previously (Gaziano et al., 2016 
| Data analysis
In planning the study, sample size calculations were performed using the CaTS software (Skol, Scott, Abecasis, & Boehnke, 2006) . We used a onestage design, an alpha level of 5 × 10 −8 for each marker, and a multiplicative inheritance model. Both dominant and recessive disease inheritance models were considered, and MAF was varied between 0.1 and 0.5. Prior to having access to MVP data, we projected (conservatively) a PTSD prevalence of 9%, as well as sample sizes of 10,000 cases (as the limiting factor) and >10,000 controls. For these assumptions and statistical power of 80%, the minimal odds ratio for discovering association between SNPs and PTSD ranged between 1.12 and 1.97.
Association tests will be performed using logistic regression models implemented in the PLINK software package (http://pngu. mgh.harvard.edu/~purcell/plink/), adjusted for age, sex, and the principal components of ancestry, determined with the Eigensoft package (http://www.hsph.harvard.edu/alkes-price/software/). Other options include fastPCA (Galinsky et al., 2016) to infer principal components and RVTESTS (Zhan, Hu, Li, Abecasis, & Liu, 2016) for association analysis. Genetic effects will be modeled as additive effects of each copy of the minor allele. Because our samples will be genetically heterogeneous, European American and African American participants will be analyzed separately. European Americans and African Americans will also be meta-analyzed together to uncover additional support for risk loci shared between these populations and for fine mapping.
In addition to SNP-based analysis, we will incorporate prior biological knowledge (e.g., pathway information, gene expression networks, and interaction networks) to identify genes and SNPs associated with PTSD and related phenotypes. These gene-based results can be summarized to identify pathways enriched for genes showing association signals (Ballard, Abraham, Cho, & Zhao, 2010) . Pathway topological information may also be informative regarding genetic associations (Chen, Cho, & Zhao, 2011 ). We will consider functional impact of putative causal variants as described elsewhere (Lu, Powles, Wang, He, & Zhao, 2016 ). We will also explore gene-gene (G × G) and gene-environment (G × E) interactions, including pathway-based interaction analysis to reduce the search space (Chen et al., 2011) , and gene-environment interaction at a genome-wide level (Polimanti et al., 2018) .
3 | RESULTS
| MVP participants' demographics and health characteristics
Between launch of the MVP in 2011 and September 2018, over 4.5 million invitations were mailed to eligible veterans, and walk-ins (n = 83,097).
Other service-related measures in Table 1 (n = 21,510) of combat-exposed veterans. Depression was the most commonly endorsed disorder at 25.4% (n = 44,034); panic disorder was reported by 14.3% (n = 24,749) and memory loss by 9.3%
(n = 16,155).
| Optimizing threshold probability for case/control definition
To minimize false-positive and false-negative attributions, the algorithm for automating selection of cases and controls used a probabilistic approach, which generates probabilities, related to trait severity, of membership in each of three classes. The threshold probability, π min (=π opt ), selected for classification as a definite case or control maximized the statistical power to detect association between SNPs and disease. As shown in Table 3 , for a disease prevalence of 30% as cited in the study protocol, various combinations of π min , MAF, and RR of disease for an allele were simulated. A π min of 0.7 for cases and controls maximized power, with results largely insensitive to MAF and RR. Based on comparisons of telephone interview results with algorithm predictions using these threshold probabilities, refinements were made to the model, including imposition of PCL ≤ 30
for predicted controls to be classified as such, to minimize false negatives.
| Algorithm performance
The performance of the algorithm can be evaluated by comparing its predictions with results of 500 chart reviews conducted by five experts at three different VA centers; see Table 4 The probabilistic approach thus resulted in reasonably accurate predictions, while providing flexibility for performing sensitivity analysis by varying the threshold probability that a deterministic algorithm cannot. By applying the algorithm to the 74,901 combat-exposed, genotyped MVP participants without a diagnosis of schizophrenia and bipolar disorder, and after discarding possible cases (i.e., Pr(case) ≤ 0.7
and Pr(control) ≤ 0.7) and imposing the PCL ≤ 30 criterion for predicted controls, we identified 16,490 PTSD cases (i.e., Pr(case) > 0.7) and 33,609 controls (i.e., Pr(control) > 0.7).
| DISCUSSION
The high prevalence of military veterans with combat exposure (see Table 1 ), which is a strong risk factor for PTSD and other comorbidities including suicidality, provides motivation for the current study. non-PTSD controls, provides a strong foundation to conduct a GWAS.
Additional information can be derived from the noncombat-exposed subjects, some of whom have PTSD attributable to other stressors.
In addition to uncertainties associated with previous genomic studies, the definition of PTSD itself has evolved recently (DiMauro, Carter, Folk, & Kashdan, 2014; Galatzer-Levy & Bryant, 2013; Kirkbride, 2012) . In particular, recent changes in PTSD criteria from DSM-IV to DSM-5 (Calhoun et al., 2012; Weathers et al., 2018) may represent a challenge, inasmuch as the algorithm and chart review activities were primarily informed by DSM-IV criteria, whereas the telephone interview uses CAPS-5, which is based on DSM-5 but "downward compatible" (Weathers et al., 2018) . a large sample size (as with MVP) can quench relatively minor differences in phenotypic definition, such as the difference between DSM-IV and DSM-5 PTSD diagnoses. This situation has been observed for related conditions, such as major depressive disorder (Wray et al., 2018 ). In the current context, accurate DSM-IV and DSM-5 PTSD are much closer to each other than the differences between either of these and non-PTSD. Albeit limited by small sample size, the agreement between our chart review results using primarily DSM-IV criteria and our telephone interview results using DSM-5 criteria is encouraging.
A related methodological issue is the challenge of using data from EHRs for phenotyping (Ouyang et al., 2016; Sinnott et al., 2014) . Accuracy of data in these records is variable, and extracting information can be challenging. To automate selection of cases and controls, we adopted a probabilistic methodology to minimize both false-negative and falsepositive designations. An algorithm was constructed and refined based on EHR chart reviews and telephone interviews, with substantial agreement noted between algorithm predictions and results from both chart reviews and telephone interviews. For the primary analysis, which will classify PTSD as a binary case/control trait, the algorithm identified adequate numbers of cases and controls, despite eliminating the possible cases (given the large size of the MVP study population). By eliminating the possible cases, we are more confident in the predicted case/control status of each study participant.
The probabilistic approach of defining PTSD caseness as a continuous (as opposed to a discrete) outcome permits sensitivity analyses to refine further the definition of PTSD. Based on the number of positive PTSD symptoms or probability of PTSD caseness, the condition can also be considered as a quantitative trait. This approach, which has been used in substance use disorder studies (Gelernter et al., 2015) , enhances statistical power because it assigns greater weight to the severely affected than to the moderately affected or to those without an unequivocal diagnosis.
In conclusion, the probabilistic approach has identified large samples of combat-exposed cases and controls, with potential for the ongoing GWAS to identify genetic markers to aid the etiological understanding and treatment of PTSD. 
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